Citigroup restated their neutral rating on shares of Indivior (LON:INDV) in a report issued on Monday.
Several other brokerages also recently weighed in on INDV. Numis Securities downgraded Indivior to a hold rating in a report on Wednesday, July 11th. Morgan Stanley cut their price target on Indivior from GBX 455 ($5.95) to GBX 398 ($5.20) and set an equal weight rating on the stock in a report on Tuesday, June 19th. Finally, Jefferies Financial Group cut their price target on Indivior from GBX 250 ($3.27) to GBX 245 ($3.20) and set a buy rating on the stock in a report on Thursday, October 11th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of GBX 378.60 ($4.95).
Shares of LON INDV opened at GBX 199.50 ($2.61) on Monday. Indivior has a 1-year low of GBX 246.50 ($3.22) and a 1-year high of GBX 436.60 ($5.70).
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Recommended Story: Diversification in Your Portfolio
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.